SQZ Biotechnologies (OTCMKTS:SQZB) is a clinical-stage biotechnology company focused on developing novel cell therapies through its proprietary microfluidic delivery technology. The company’s core “Cell Squeeze” platform temporarily disrupts cell membranes to enable direct intracellular delivery of a wide range of biomolecules, including proteins, peptides and nucleic acids, without relying on viral vectors. This approach is designed to improve manufacturing efficiency, enhance safety profiles and broaden the applicability of cell-based therapies across multiple disease areas.
The company’s pipeline spans oncology, infectious disease and regenerative medicine. In oncology, SQZ is advancing cell therapies aimed at mobilizing the patient’s own immune cells against tumors. Its infectious disease programs seek to harness antigen-presenting cells for next-generation vaccine development. Additionally, SQZ is exploring applications in regenerative medicine by delivering gene-editing tools and growth factors directly into target cells.
SQZ Biotechnologies has established partnerships with leading pharmaceutical organizations, including a collaboration with Roche to develop cell-based oncology vaccines and a discovery agreement with Merck to explore immuno-oncology applications. While its headquarters and primary research and manufacturing facilities are located in Cambridge, Massachusetts, the company supports clinical trials and collaborative research efforts across North America and Europe.
Founded in 2013 by Armon Sharei and Daniel J. Anderson, SQZ Biotechnologies has grown from an academic laboratory at MIT’s Koch Institute into a publicly traded company. Co-founder Armon Sharei serves as Chief Executive Officer, bringing extensive expertise in drug delivery and bioengineering, while Dr. Anderson remains an active scientific advisor. Under this leadership, SQZ continues to advance its platform with the goal of bringing transformative cell therapies to patients.
AI Generated. May Contain Errors.
